Key result
Astragaloside IV reduces myocardial fibrosis in animal studies via collagen metabolism, anti-apoptosis, and anti-inflammation.
Why the study?
Astragaloside IV has beneficial effects against cardiovascular disease, but its anti-fibrosis effects across animal models and underlying mechanisms needed systematic summarization to guide potential clinical use.
Does astragaloside IV improve myocardial fibrosis in animal models of cardiovascular diseases?
Systematic Review (n=24)
Does astragaloside IV improve myocardial fibrosis in animal models of cardiovascular diseases?
Astragaloside IV demonstrates promising anti-fibrotic effects in preclinical models of cardiovascular disease through multiple mechanisms, though clinical and toxicological data are currently lacking.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open human trials to confirm translation of preclinical anti-fibrotic effects.
CONTEXT: Fisch. ex Bunge Fabaceae, possesses diverse biological activities that have beneficial effects against cardiovascular disease. OBJECTIVE: This systematic review aims to summarize the anti-fibrosis effect of AS-IV in animal models (rats or mice only) and its underlying mechanisms, and provide potential directions for the clinical use of AS-IV. METHODS: PubMed, EMBASE, Web of Science, CNKI, Wanfang database, and SinoMed were searched from inception to 31 December 2024. The following characteristics of the included studies were extracted and summarized: animal model, route of administration, dose/concentration, measurement indicators, and potential mechanisms. The quality of the included studies was assessed used a 10-item scale from SYRCLE. RESULTS AND CONCLUSION: AS-IV represents a promising multi-target candidate for myocardial fibrosis treatment in the 24 eligible studies included in the analysis. This systematic review is the first to comprehensively evaluate the anti-fibrosis mechanisms of AS-IV across heterogeneous cardiovascular disease animal models, including myocardial infarction, hypertension, ischemia-reperfusion injury, and myocarditis. The underlying mechanisms of the anti-fibrosis effects of AS-IV may include collagen metabolism, anti-apoptosis, anti-inflammation and, pyroptosis, antioxidants, improving mitochondrial function, regulating senescence, etc. Current evidence remains preclinical, with critical gaps in toxicological profiles, human safety thresholds, and clinical adverse reaction data. Future research must integrate robust toxicological evaluations, optimized combination therapies, and adaptive clinical trials to validate translational potential.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) conducted a systematic review in Cardiovascular diseases (myocardial infarction, hypertension, ischemia-reperfusion injury, and myocarditis) (n=24). Astragaloside IV (AS-IV) was evaluated on Anti-fibrosis effect and underlying mechanisms. Astragaloside IV represents a promising multi-target candidate for myocardial fibrosis treatment across 24 animal studies, acting via collagen metabolism, anti-apoptosis, and anti-inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: